UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $65.59 Million Position in Inspire Medical Systems, Inc. (NYSE:INSP)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 3.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 353,835 shares of the company's stock after selling 11,333 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.18% of Inspire Medical Systems worth $65,594,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Merit Financial Group LLC bought a new position in Inspire Medical Systems during the 4th quarter valued at $313,000. Nisa Investment Advisors LLC boosted its stake in shares of Inspire Medical Systems by 37.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 368 shares of the company's stock valued at $68,000 after buying an additional 100 shares during the period. SG Americas Securities LLC increased its position in Inspire Medical Systems by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 3,534 shares of the company's stock worth $655,000 after purchasing an additional 892 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Inspire Medical Systems by 248.5% during the 4th quarter. Janney Montgomery Scott LLC now owns 4,806 shares of the company's stock worth $891,000 after purchasing an additional 3,427 shares during the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Inspire Medical Systems by 19.8% during the 4th quarter. Fifth Third Bancorp now owns 1,623 shares of the company's stock worth $301,000 after acquiring an additional 268 shares in the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 360 shares of the company's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $160.00, for a total value of $57,600.00. Following the completion of the transaction, the director now owns 24,046 shares of the company's stock, valued at $3,847,360. This represents a 1.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.10% of the stock is currently owned by insiders.

Inspire Medical Systems Stock Performance

Shares of INSP stock traded down $0.50 during midday trading on Friday, hitting $137.75. 170,738 shares of the company were exchanged, compared to its average volume of 558,805. The firm's 50 day moving average price is $151.99 and its two-hundred day moving average price is $173.56. The firm has a market capitalization of $4.06 billion, a P/E ratio of 79.63, a PEG ratio of 2.86 and a beta of 1.39. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $225.00.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.33. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The company had revenue of $201.32 million during the quarter, compared to the consensus estimate of $194.89 million. During the same period in the previous year, the business earned ($0.34) earnings per share. The firm's quarterly revenue was up 22.7% on a year-over-year basis. Analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Analyst Upgrades and Downgrades

INSP has been the subject of a number of recent research reports. Wells Fargo & Company cut their target price on Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird upped their target price on shares of Inspire Medical Systems from $230.00 to $236.00 and gave the company an "outperform" rating in a research note on Tuesday, May 6th. Royal Bank of Canada lowered their target price on Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating for the company in a research note on Tuesday, April 15th. Finally, Morgan Stanley reduced their price objective on Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $211.91.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.